Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Earns Key CMS Approval, Streamlining Access to Molluscum Contagiosum Treatment

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has achieved a significant milestone in its commercial strategy. The Centers for Medicare & Medicaid Services (CMS) has issued a permanent …

Verrica Pharmaceuticals Earns Key CMS Approval, Streamlining Access to Molluscum Contagiosum Treatment Read More

Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leader in dermatology therapeutics, announced a significant development in its ongoing research for innovative skin cancer treatments. The company confirmed …

Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy Read More

Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics provider, has shared promising top-line results from the Phase 3 trial of TO-208 for molluscum contagiosum (“molluscum”) …

Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan Read More

Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference, which is being …

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London Read More